Ikaria is committed to continually improving delivery systems for safe dosing and administration of INOMAX |
INOMAX® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
INOMAX Important Safety Information (ISI)
INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
INOMAX Delivery Systems
The Food and Drug Administration (FDA) requires that INOMAX (nitric oxide) for inhalation be delivered through special drug delivery systems that meet specific criteria.
INOMAX delivery systems:
- Allow for operator-determined concentrations of nitric oxide in the breathing gas
- Provide for a concentration that is constant throughout the respiratory cycle
- Monitor for nitric oxide (NO), oxygen (O2), and nitrogen dioxide (NO2)
- Prevent generation of excessive inhaled NO2
 INOmax DS developed for bedside or transport situations. It meets all of the FDA-required specifications for INOMAX drug delivery. |
 INOvent a bedside delivery system for INOMAX. It meets all of the FDA-required specifications for INOMAX drug delivery systems. |
FUTURE delivery systems with improved technology continue to be a top priority for Ikaria.